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Summary: The incidence of non-tuberculous mycobacterial (NTM) infections is increasing 
worldwide. Our systematic review and meta-analysis suggest that BCG vaccination has a 
protective effect against NTM lymphadenitis and Buruli ulcer. This has important 
implications, in particular when deciding on recommendations for discontinuation of 
universal BCG vaccination programmes. 
 
Abstract 
The incidence of non-tuberculous mycobacterial (NTM) infections is increasing worldwide, 
particularly NTM lymphadenitis and skin infections (Buruli ulcer). This review summarises the 
evidence for the protective effectiveness of Bacillus Calmette–Guérin (BCG) vaccination against NTM 
disease. A systematic search using PRISMA guidelines was done for controlled studies investigating 
the protective effectiveness of BCG vaccination against NTM disease in immunocompetent 
individuals. This revealed ten studies, including almost 12 million participants. Three cohort studies in 
industrialised countries suggest that the incidence of NTM lymphadenitis is greatly reduced among 
BCG-vaccinated children compared to BCG-unvaccinated children, with a risk ratio (RR) of 0.04 (95% 
confidence interval (CI) 0.01 to 0.21). In two randomised trials in low-income countries, BCG 
protected against Buruli ulcer for the first 12 months following vaccination, RR 0.50 (95% CI 0.37 to 
0.69). Four case control studies had conflicting results. One cohort study found that individuals with 
Buruli ulcer are less likely to develop osteomyelitis if they have a BCG scar, RR 0.36 (95% CI 0.22 to 
0.58). No studies have compared different BCG vaccine strains or the effect of revaccination in this 
setting.  
The protective effect of BCG vaccination against NTM should be taken into consideration when 
deciding on recommendations for discontinuation of universal BCG vaccination programs and in 
assessing new vaccines designed to replace BCG.  
Keywords: NTM, nontuberculous, atypical, mycobacteria, lymphadenitis, epidemiology, prevention, 
Buruli ulcer, M. ulcerans, M. avium, MAC  
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Introduction 
Non-tuberculous mycobacteria (NTM) are ubiquitous, being found in water, soil and animals. 
Although more than 170 species have been identified, the majority of human NTM disease is caused 
by fewer than 20 species [1]. In immunocompetent children, NTM most frequently cause 
cervicofacial lymphadenitis or skin and soft tissue infections. The commonest NTM skin infection 
worldwide is Buruli ulcer, a chronic, progressive skin lesion, caused by Mycobacterium ulcerans. 
Untreated, the ulcer can progress to osteomyelitis and lead to permanent bone destruction. 
  
Although not a notifiable disease, the incidence of NTM lymphadenitis in industrialised countries is 
reported to be between 0.6 and 2.2 cases per 100,000 children per year [2-4], with the highest 
incidence in children below 4 years of age. Epidemiological studies in developing countries are 
lacking. Buruli ulcer has been reported in 33 countries and 15 countries regularly provide data to the 
World Health Organization (WHO) [5]. The incidence in Africa is estimated to be between 21 and 320 
cases per 100,000 per year [6, 7] in Australia, at 1 case per 100,000 per year [5, 8], and in Japan at 
0.005 cases per 100,000 per year. In Africa, about half of the cases occur in children under 15 years, 
whereas in Australia and Japan approximately 15% of cases occur in this age group [5]. 
 
Over the past few decades, the reported incidence of NTM lymphadenitis, as well as Buruli ulcer, has 
been increasing [6, 7, 9-12]. This might be attributable partly to improved awareness, enhanced 
reporting and better diagnostic methods, but it is also possible that the apparent increase is related 
to the discontinuation of Bacillus Calmette-Guérin (BCG) vaccination programmes in industrialised 
countries. As BCG vaccine is a live attenuated strain of M. bovis that shares epitopes with NTM, it is 
plausible that it provides specific cross-protection against NTM disease. This review and meta-
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analysis summarises all studies that have investigated the protective effectiveness of BCG vaccination 
against NTM disease in immunocompetent children and adults. 
 
Search strategy  
A systematic search was done according to the preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) [13] for studies investigating the protective effectiveness of Bacillus 
Calmette–Guérin (BCG) vaccination against NTM disease. In April 2017, MEDLINE (1946 to present) 
and Embase (1947 to present) were searched using the Ovid interface with the following search 
terms: (nontuberculous OR non-tuberculous OR NTM OR atypical mycobacteria OR environmental 
mycobacteria OR Buruli ulcer OR Mycobacterium avium OR Mycobacterium ulcerans OR 
Mycobacterium avium-intracellulare) AND (BCG vaccin* OR Mycobacterium bovis) without language 
limitations. The references of identified articles were hand-searched for further studies. The 
following variables were extracted from the included studies: year of study, country, study design, 
number of participants, age of participants, BCG vaccination status, BCG vaccine strain, NTM disease, 
diagnostic methods and key findings. Review Manager (version 5.3) was used for calculation of 
relative risks, odds ratios and the meta-analyses. Diversity in study design and reporting, which might 
result in selection and reporting bias, precluded quality evaluation according to the PRISMA 
guidelines. The ROBINS-1 tool [14] was used to assess risk of bias (table 4). 
 
Results 
The literature searches yielded 812 articles relating to NTM and 1543 articles relating to 
Buruli ulcer. Of these, 10 fulfilled the inclusion criteria of controlled studies investigating the 
protective effectiveness of BCG vaccination against NTM disease in immunocompetent 
individuals. One study was excluded because it included the same patients as one of the other 
identified studies [15]. 
Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiy207/4964710
by  petrasabine.zimmermann@gmail.com
on 15 April 2018
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
NTM lymphadenitis in industrialised countries  
Three studies from industrialised countries, all population-based cohort studies, compared the 
incidence of NTM lymphadenitis in a total of 9,888,719 BCG-vaccinated children with 1,960,572 non-
BCG vaccinated children. Of these children, 445 were diagnosed with NTM disease. All three studies 
reported a greatly reduced incidence of NTM lymphadenitis in BCG-vaccinated compared to BCG-
unvaccinated children: the overall risk ratio (RR) was 0.04 (95% confidence interval (CI) 0.01 to 0.21) 
(table 1 and figure 1). The number needed to treat (NNT) calculated from the three cohort studies 
was 4835 (95% CI 4403 to 5362). 
 
A nationwide surveillance study in Sweden, done after discontinuation of routine neonatal BCG 
vaccination, reported 387 children with confirmed extrapulmonary NTM disease (83% with 
Mycobacterium-avium-intracellulare complex (MAC), 97% presenting with lymphadenitis) over a 
period of 22 years. Only 9 of the 390 children had received BCG vaccine (0.02%). The cumulative 
incidence rate of NTM infection was 5.9 per 100,000 in BCG-vaccinated children below the age of 5 
years and 26.8 per 100,000 in BCG-unvaccinated children [16]. Similarly, a study from the Czech 
Republic after discontinuation of routine BCG vaccination, in which children were screened for NTM 
disease by skin test, reported 27 cases of MAC lymphadenitis over a period of 6 years. All the cases 
occurred in BCG-unvaccinated children with an incidence of NTM lymphadenitis of 3.6 per year per 
100,000 [17]. In Finland, during the period when BCG vaccine was routinely administered to 
newborns, the incidence of NTM lymphadenitis between 1 and 4 years of age was 0.3 per 100,000 
per year in BCG-vaccinated children and 1.5 to 2.5 per year in BCG-unvaccinated children [18]. 
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Six studies investigated the protective effectiveness of BCG vaccination against Buruli ulcer, 
comparing the incidence in 6,475 BCG-vaccinated adults and children with 13,612 BCG-unvaccinated 
adults and children. The strongest evidence comes from two randomised controlled trials (RCT) done 
in Uganda (table 2a and figure 2a). These reported a considerably lower incidence of Buruli ulcer in 
BCG-vaccinated participants compared to BCG-unvaccinated with a RR of 0.50 (95% CI 0.37 to 0.69). 
The number needed to treat (NNT) calculated from the three cohort studies was 4835 (95% CI 4403 
to 5362). The number needed to treat (NNT) calculated from the three cohort studies was 4835 (95% 
CI 4403 to 5362). Protection following BCG vaccination was higher in low-incidence than in high-
incidence settings (74% vs 18%, p=0.03) [19] and was only short-term (within the first year after 
vaccination), with an overall reduction of Buruli ulcer of 47% (p=0.007, p<0.01).[19, 20] In one of 
these studies, BCG-vaccinated individuals had smaller skin lesions compared with unvaccinated 
individuals [20]. 
 
Four case control studies (two from Benin, one from Ghana, and one from the Congo, Ghana and 
Togo) investigated the protective effectiveness of BCG against Buruli ulcer (table 2b). Two studies 
suggest a reduced risk of Buruli ulcer in BCG-vaccinated individuals [21, 22], and two suggest no 
benefit [26, 27]; when the results of all four case control studies are combined there is no evidence 
of a protective effect of BCG, odds ratio OR 1.34 (95% CI 0.19 to 1.51) (figure 2b) [21-25]. 
 
Osteomyelitis 
One cohort study from Benin compared the incidence of osteomyelitis in patients with Buruli 
ulcer in 304 BCG-vaccinated adults and children with the incidence in 68 BCG-unvaccinated 
adults and children (table 3 and figure 3). This showed that BCG vaccination protected 
against the development of osteomyelitis in patients with Buruli ulcer (RR 0.36 (95% CI % 
Buruli ulcer 
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0.22 to 0.58)) [26]. However, the study did not specify how many cases were laboratory 
confirmed and therefore inclusion of osteomyelitis caused by pathogens other than NTM 
might have led to an overestimate of the rate of protection. 
 
Discussion 
The protective effectiveness of BCG vaccination against Mycobacterium tuberculosis and 
Mycobacterium leprae is well recognised [27, 28]. There is also evidence that infection with NTM 
might confer protection against M. tuberculosis infection or interact with the effectiveness of BCG 
vaccination [29-31]. In contrast, whether BCG vaccination protects against NTM infections has been 
controversial.  
 
Our review found strong evidence from large European surveillance studies that BCG vaccination 
protects against NTM lymphadenitis in children. The rate of NTM infections in Finland, when there 
was universal neonatal BCG vaccination, was 30 times lower than the rate in Sweden, which did not 
have universal neonatal BCG vaccination, despite both countries having similar environmental and 
epidemiological characteristics [18]. In addition, in the Czech Republic and in Sweden, a sharp 
increase in NTM infection in children was observed after stopping universal neonatal BCG vaccination 
[16, 17].  
For Buruli ulcer, there is strong evidence from two RCTs for a protective effect of BCG vaccination in 
the first year after the vaccination [19, 20].The results of the case control studies are difficult to 
interpret given their disparate findings. Furthermore, it is important to consider that the RCTs 
estimated the effectiveness of BCG vaccine under the optimal storage, handling and administration 
conditions of a clinical trial [19, 20], whilst this was not necessarily the case in the case control 
studies [21-23, 25]. In addition to the study included in our review which reports smaller skin lesions 
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in patients with Buruli ulcer who have previously received a BCG vaccine [20], another study (not 
included in this review because the BCG vaccination status was not reported in the control group) 
reported a shorter duration to healing [24]. A further study (not included due to incomplete data) 
suggested that BCG vaccination protects against severe forms of Buruli ulcer with multiple skin 
lesions.[32] As well as the evidence from the study included in our review [26], another study (not 
included as there was no control group), also indicates that BCG vaccination might protect patients 
with Buruli ulcer from progression to NTM osteomyelitis.  
 
Notably, all but one of the studies reporting on the protective effect of BCG vaccination against 
Buruli ulcer assessed BCG vaccinations status only by the presence of scar. Determining BCG 
vaccination status by the presence of a scar has a sensitivity of between 55% and 97% [33-35] and 
therefore its use may underestimate BCG vaccine effectiveness in comparative studies. However, the 
presence of a scar does not predict protection against tuberculosis [36, 37], and failure to develop a 
BCG scar might be an indication of poor vaccination technique [38]. As this might also be the case for 
NTM disease, using the presence of a scar rather than administration of BCG could, on the contrary, 
also over-estimate protection. 
 
There is some evidence to suggest that vaccine strain and genotype influences the protective 
effectiveness of BCG against M. tuberculosis [39-41]. It is therefore plausible that there is variation 
between different BCG strains in their protective effectiveness against NTM disease. The vaccine 
strains used in the studies included in this review varied considerably, precluding meaningful 
analysis. 
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A trial that included 121,020 people in Malawi showed that revaccination with BCG approximately 
halved the risk of leprosy compared with a single BCG vaccination, even though it did not protect 
against pulmonary tuberculosis [42]. It would be of interest to determine whether revaccination with 
BCG increases the strength or duration of protection against non-tuberculous mycobacteria. 
 
A number of animal studies support the notion that BCG vaccination protects against NTM infection. 
Mice, rabbits and guinea pigs vaccinated intracutaneously with BCG Dubos II are protected against 
M. avium administered intravenously [43]. Mice vaccinated with BCG Pasteur or Glaxo 
subcutaneously, intravenously or through the aerogenic route are protected against aerogenic 
infection with M. avium and M. kansaii, but not against M. simiae or M. intracellulare [44, 45]. One 
study in mice found that the effectiveness of BCG vaccination against NTM infection varies according 
to differences in host conditions and different strains of M. ulcerans [46]. 
 
Recent trials have investigated the possibility of developing vaccines with greater effectiveness 
against NTM. The mycobacterial antigen 85A has 85% amino acid sequence similarity in M. 
ulcerans and M. bovis. A DNA vaccine encoding this antigen protects mice against Buruli ulcer [47]. 
This vaccine has been further developed, combining antigen 85A from M. smegmatis with BCG in a 
live-recombinant vaccine, and protects mice against Buruli ulcer [48]. A single immunisation with a 
plasmid expressing the BCG antigen DNA-35 protects mice against infection with M. avium [49]. 
 
The strengths of this review are the comprehensive literature search, the clearly defined inclusion 
criteria and the use of meta-analysis to assess results from multiple studies. The main limitations are 
the heterogeneity between studies in design, including the use of different BCG strains. Further 
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limitations are potential differences between the groups who received and did not receive BCG 
vaccine, such as epidemiological factors, access to healthcare and intensity of surveillance. 
Additionally, the use of BCG scar to assess vaccination status in retrospective studies and the 
inclusion of non-laboratory confirmed cases of NTM infection probably introduces bias. The risk of 
bias in the studies is summarised in table 4.   
 
Overall, our review and meta-analysis indicates that BCG vaccination protects against NTM. It is likely 
that effectiveness of BCG vaccination varies between different NTM diseases, populations, age 
groups and the BCG strain used to vaccinate. The increase in incidence of NTM lymphadenitis in 
industrialised countries that have discontinued universal BCG vaccination might therefore be related 
to the loss of protection afforded by this vaccine. 
 
Our review suggests that the protective effect of BCG vaccination against NTM should be taken into 
consideration when deciding on recommendations for discontinuation of universal BCG vaccination 
programmes and in assessing new vaccines designed to replace BCG. In deciding vaccine policy, the 
incidence and the severity of the disease, as well as the NNT are important considerations. The NNT 
with BCG vaccine to prevent one case of NTM lymphadenitis is probably unjustifiably high when 
considered in isolation, as NTM lymphadenitis is relatively rare and usually has a favourable 
outcome, despite a frequently long and troublesome course. In contrast, Buruli ulcer is a serious 
condition with crippling sequelae, and has been identified by the WHO as an emerging public health 
problem. The potential importance of BCG vaccination for preventing Buruli ulcer has been 
recognised in a recent WHO position paper [50]. 
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Table 1 Studies reporting on the protective effect of BCG vaccination against non-tuberculous mycobacterial lymphadenitis in industrialised countries
1 
 
Author 
Study period 
Study location 
Age of 
participants 
 
Study type 
(level of 
evidence) 
Outcome 
Diagnostic methods 
Vaccine strain 
 
No. of cases  Relative risk 
(95% CI) 
 
 
Key findings, comments  
including NTM species cultured 
  BCG-vaccinated  BCG-
unvaccinated 
Katila et al [18] 
1977-1986 
Finland 
Children 
 
Retrospective 
population-
based cohort  
study 
(2C) 
Lymphadenitis  
clinical 31  
histology 31 
skin test 10 
culture 11 
1977 BCG Sweden 
1978-1986 BCG Glaxo 
25
1
/8,333,333 
 
6
1
/300,000 
 
0.15  
(0.06 to 0.37) 
 
 
BCG reduces the risk of NTM infection 
 highest protection at 1-4 years of age 
 35% of cases were laboratory confirmed
2
 
 MAC 9, M. malmoense 2 
 vaccine status determined by vaccination record 
  
Trnka et al [17] 
1986-1993 
Czech Republic 
Children Prospective 
population-
based cohort  
study 
(2C) 
Lymphadenitis  
clinical 27  
histology 27  
skin test 15  
culture 4 
BCG Russia 
 
0/746,087  
 
27/190,874 
 
0.00  
(0.00 to 0.08) 
 
BCG vaccination reduces the risk of MAC lymphadenitis 
 15% of cases were laboratory confirmed
2
 
 cervical 24, mediastinal 2, cervical plus mediastinal 1 
 vaccine status determined by vaccination record 
 
Romanus et al 
[16] 
1969-1990 
Sweden 
Children 
<15y 
 
Retrospective 
and prospective 
population-
based cohort  
study 
(2C) 
Extrapulmonary NTM 
infection 
clinical 387 
culture confirmed 387 
1969-1978 BCG Sweden 
1978-1990 BCG Denmark 
8/809,299 379/1,469,698 0.04  
(0.02 to 0.08) 
BCG vaccination reduces the risk of NTM infection 
 lymphadenitis/soft tissue infection 379, skin infection 5, 
osteo-articular infection 2, otitis media 1 
 100% of cases were laboratory confirmed
2
 
 MAC 321, M. malmoense 43, M. marinum 4, M. 
scrofulaceum 4, Runyon III
3
 4, non typable 4, M. 
chelonae 3, M. fortuitum 2, M. xenopi 2, M. avium 1, M. 
kansasii 1, M. terrae 1 
 vaccine status determined by vaccination record 
 
1 
includes 2-6 possible infections with M. tuberculosis  
2 
by culture or PCR  
3 
non-typed, slow growing, non-chromogenic mycobacteria  
MAC - Mycobacterium-avium-intracellulare complex 
y – year 
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Table 2a Randomised controlled trials reporting on the protective effect of BCG vaccination against Buruli ulcer 
Author 
Study period 
Study location 
Age of 
participants 
 
Study type  
(level of 
evidence) 
Outcome 
Diagnostic methods 
Vaccine strain 
 
No. of cases  Relative risk  
(95% CI) 
 
Key findings and comments 
BCG-vaccinated  BCG-
unvaccinated 
Bradley et al [19] 
1967-1968 
Uganda 
Children and 
adults  
(31% <15y) 
 
Randomised 
controlled trial 
(1B) 
Buruli ulcer  
clinical 65 
histology 63 
culture 31 
BCG Glaxo 
 
21/606  
(3%) 
44/624  
(7%) 
0.49  
(0.30 to 0.82) 
 
BCG vaccination reduced the risk of Buruli ulcer  
 overall protection rate reported as 47% (p=0.007) 
 protection was only in the first year after vaccination 
(72% protective in first 6m) 
 protection 18% in high-incidence settings, 74% in low-
incidence areas (p=0.03) 
 onset of symptoms was delayed by 2-3m in those BCG-
vaccinated  
 48% of cases were laboratory confirmed
1
 
Smith et al [20] 
1970-1974 
Uganda 
Children and 
adults  
(48% <15y) 
 
Randomised 
controlled trial 
(1B) 
Buruli ulcer 
clinical 100 
histology 48 
BCG Glaxo 
 
34/2775  
(1%) 
 
66/2764 
(2%)  
0.51  
(0.34 to 0.77) 
 
BCG vaccination reduced the risk of Buruli ulcer  
 overall protection rate reported as 47% (p<0.01) 
 protection was only in the first year after vaccination 
(63% protective in first 12m) 
 protective only in participants with tuberculin reactions of 
<4mm before vaccination (p<0.05) 
 BCG vaccinated individuals had smaller skin lesions 
(p<0.01) 
 no cases were laboratory confirmed
1
 
 retrospective case-control part of study: RR 0.78 (0.50 
to 1.21) 
 
1 
by culture or PCR  
m - month 
y - year 
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Table 2b Case control studies reporting on the protective effect of BCG vaccination against Buruli ulcer 
Author 
Study period 
Study location 
Age of 
participants 
 
No. of participants Study type 
(level of 
evidence) 
Outcome 
Diagnostic 
methods 
Vaccine strain 
 
No. of cases Odds ratio 
(95% CI) 
 
Key findings and comments 
BCG- 
vaccinated  
Non-BCG-
vaccinated 
 BCG+/ 
cases 
BCG+/ 
controls 
Raghunathan et 
al [23] 
2000 
Ghana 
Children and 
adults  
(62% < 15y) 
 
119 113 Retrospective 
case control 
study 
(3B) 
Buruli ulcer  
clinical 116 
histology 79 
stain 13 
culture 54  
PCR 106 
Various strains 
 
63/116  
(54%) 
56/116 
(48%) 
 
1.27  
(0.76 to 2.13) 
 
BCG vaccination does not reduce the risk of Buruli 
ulcer 
 approximately 95% of cases were laboratory 
confirmed
1
 
 vaccine status determined by presence of scar 
Debacker et al 
[25] 
1997-2003 
Benin 
Children and 
adults  
(38% < 15y) 
1907 817 Retrospective 
case control 
study 
(3B) 
Buruli ulcer 
clinical 1453 
Various strains 
 
1127/1453 
(78%) 
780/1271 
(61%) 
2.18 
(1.84 to 2.57) 
BCG vaccination does not reduce the risk of Buruli 
ulcer 
 no cases were laboratory confirmed
1
 
 vaccine status determined by presence of scar 
Nackers et al 
[22] 
2002-2003 
Benin 
Children and 
adults  
(48% < 13y) 
 
279 988 Retrospective 
case control 
study 
(3B) 
Buruli ulcer  
clinical 844 
stain or 
histology or 
culture or PCR 
134 
Various strains 
 
180/844 
(21%) 
99/423  
(23%) 
0.89  
(0.67 to 1.17) 
 
BCG vaccination reduces the risk of Buruli ulcer 
 protection (adjusted for socioeconomic status) 12% 
(95% CI 24% - 37%) 
 most received BCG vaccination as neonates and 
were included >1y after vaccination 
 <16% cases were laboratory confirmed
1
 
 vaccine status determined by presence of scar or 
vaccination record 
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Phillips et al [21] 
2010-2013 
Congo, Ghana, 
Togo 
Children and 
adults  
(54% < 19y) 
 
775 452 Retrospective 
case control 
study 
(3B) 
Buruli ulcer 
clinical 401 
stain 277  
culture 56 
PCR 373 
Congo: 
2010-2011 BCG Japan 
2012 BCG Japan or 
Russia 
2013 BCG Russia 
Ghana: 
BCG Japan 
Togo: 
BCG Russia 
226/401  
(56%) 
549/826  
(66%) 
0.65  
(0.51 to 0.83) 
 
BCG vaccination reduces the risk of Buruli ulcer (but 
authors stated not after stratifying by country and age) 
 BCG vaccination does not influence duration or 
time to healing of skin lesions 
 approximately 95% of cases were laboratory 
confirmed
1
 
 vaccine status determined by presence of scar 
 
1 
by culture or PCR  
 
PCR - polymerase chain reaction 
y - year 
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Table 3 Studies reporting on the protective effect of BCG vaccination against M. ulcerans osteomyelitis in patients with Buruli ulcer 
Author 
Publication 
Year 
Study location 
Age of 
participants 
 
Study type 
(level of 
evidence) 
Outcome 
Diagnostic methods 
Vaccine strain 
 
No. cases Relative risk  
(95% CI) 
 
Key findings and comments 
  BCG-vaccinated 
 
BCG-
unvaccinated 
 
 
  
Portaels et al 
[26] 
2004 
Benin 
Children and 
adults  
(60% < 15y) 
Cohort study 
(2B) 
Osteomyelitis in 
patients with Buruli 
ulcer  
clinical 55 
stain or culture or 
PCR 55 
Not specified 34/304  
(11%) 
 
 
21/68  
(31%) 
 
 
0.36  
(0.22 to 0.58) 
 
 
BCG vaccination protects against M. ulcerans 
osteomyelitis in children and adults with Buruli ulcer 
 vaccine status determined by presence of scar 
 not specified how many cases were laboratory 
confirmed
1
 
  
1 
by culture or PCR  
 
PCR - polymerase chain reaction 
y - year 
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Table 4 Risk of bias summary of studies included in the review (1 = very low, 2 = low, 3 = moderate, 4 = high, 5 = very high) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CS – cohort study 
CCS – case control study 
RCT – randomised controlled trial 
Reference Publication 
year 
Study type Confounding Selection 
Bias 
Misclassifica
tion Bias 
Performance 
Bias 
Attrition 
Bias 
Detection 
Bias  
Reporting 
Bias 
Lymphadenitis 
Katila[18] 1987 CS 5 3 3 3 4 2 2 
Trnka[17] 1994 CS 4 1 2 4 3 5 2 
Romanus[16] 1995 CS 4 1 2 3 3 5 2 
Buruli ulcer 
Bradley[19] 1969 RCT  -  + - - - 
Smith[20] 1976 RCT  -  - - - - 
Raghunathan[23] 2005 CCS 4 3 5 3 4 3 4 
Debacker[25] 2006 CCS 5 4 5 3 5 3 4 
Nackers[22] 2006 CCS 4 4 5 3 4 3 5 
Phillips[21] 2015 CCS 5 4 4 3 4 3 4 
M. ulcerans osteomyelitis 
Portales[26] 2004 CS 3 4 5 3 4 3 4 
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Figure 1 Comparison of incidence of non-tuberculous lymphadenitis infection in BCG-vaccinated and BCG-
unvaccinated children in industrialised countries 
 
Figure 2a Comparison of incidence of Buruli ulcer in BCG-vaccinated and BCG-unvaccinated participants in 
randomised controlled  
 
 
Figure 2b Comparison of incidence of Buruli ulcer in BCG-vaccinated and BCG-unvaccinated participants in case-
control studies 
  
Figure 3 Comparison of incidence of osteomyelitis in BCG-vaccinated and BCG-unvaccinated participants with 
Buruli ulcer 
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